系统性硬化症的靶向治疗前沿与治疗反应预测指标
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis.
作者信息
Tomcik Michal
机构信息
Institute of Rheumatology, Department of Rheumatology of the First Faculty of Medicine, Charles University, Na Slupi 4, 128 00 Prague, Czech Republic.
出版信息
Biomedicines. 2022 Nov 28;10(12):3053. doi: 10.3390/biomedicines10123053.
Abstract
Systemic sclerosis (scleroderma, SSc) is one of the most challenging rheumatic diseases, characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, heart, digestive tract, and kidneys [...].
摘要
系统性硬化症（硬皮病，SSc）是最具挑战性的风湿性疾病之一，其特征为血管病变、免疫反应失调以及影响皮肤、肺、心脏、消化道和肾脏的进行性组织纤维化[...]。
相似文献
1
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis.系统性硬化症的靶向治疗前沿与治疗反应预测指标
Biomedicines. 2022 Nov 28;10(12):3053. doi: 10.3390/biomedicines10123053.
2
The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review.系统性硬皮病血管病变中内皮细胞的作用：系统评价。
Autoimmun Rev. 2017 Aug;16(8):774-786. doi: 10.1016/j.autrev.2017.05.024. Epub 2017 May 29.
3
Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.硬皮病的临床治疗选择：建议和综合评价。
Clin Rev Allergy Immunol. 2022 Apr;62(2):273-291. doi: 10.1007/s12016-020-08831-4. Epub 2021 Jan 15.
4
Targeted delivery in scleroderma fibrosis.硬皮病纤维化中的靶向递送
Autoimmun Rev. 2021 Feb;20(2):102730. doi: 10.1016/j.autrev.2020.102730. Epub 2020 Dec 16.
5
Type I interferon dysregulation in Systemic Sclerosis.Ⅰ型干扰素失调与系统性硬化症。
Cytokine. 2020 Aug;132:154635. doi: 10.1016/j.cyto.2018.12.018. Epub 2019 Jan 23.
6
Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin.建立一种人类系统性硬化症动物模型，使系统性硬化症患者的 T 辅助细胞-17 浸润并导致肺部和皮肤纤维化。
Exp Mol Med. 2022 Sep;54(9):1577-1585. doi: 10.1038/s12276-022-00860-7. Epub 2022 Sep 29.
7
Purinergic signalling in systemic sclerosis.嘌呤能信号在系统性硬化症中的作用。
Rheumatology (Oxford). 2022 Jul 6;61(7):2770-2782. doi: 10.1093/rheumatology/keab859.
8
The heart and pulmonary arterial hypertension in systemic sclerosis.系统性硬化症中的心脏和肺动脉高压。
Acta Clin Belg. 2016 Feb;71(1):1-18. doi: 10.1080/17843286.2015.1108538. Epub 2016 Feb 5.
9
The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.血小板在自身免疫、血管病变和纤维化中的作用：对系统性硬化症的影响。
Semin Arthritis Rheum. 2017 Dec;47(3):409-417. doi: 10.1016/j.semarthrit.2017.05.004. Epub 2017 May 23.
10
Mesenchymal stromal cells for systemic sclerosis treatment.间充质基质细胞治疗系统性硬化症。
Autoimmun Rev. 2021 Mar;20(3):102755. doi: 10.1016/j.autrev.2021.102755. Epub 2021 Jan 18.
本文引用的文献
1
Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis.自身抗体作为系统性硬化症的生物标志物和治疗靶点
Biomedicines. 2022 Sep 1;10(9):2150. doi: 10.3390/biomedicines10092150.
2
Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry.肺活量测定正常的系统性硬化症相关间质性肺疾病患者肺功能下降的临床预测因素
Biomedicines. 2022 Aug 31;10(9):2129. doi: 10.3390/biomedicines10092129.
3
MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors.系统性硬化症合并肺动脉高压患者中的微小RNA：标志物与效应分子
Biomedicines. 2022 Mar 8;10(3):629. doi: 10.3390/biomedicines10030629.
4
Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis.血浆代谢组学分析揭示了系统性硬化症中四种可能受到干扰的机制。
Biomedicines. 2022 Mar 4;10(3):607. doi: 10.3390/biomedicines10030607.
5
Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease.系统性硬化症随机临床试验的新证据与治疗前景：聚焦间质性肺疾病
Biomedicines. 2022 Feb 21;10(2):504. doi: 10.3390/biomedicines10020504.
6
Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox.治疗与系统性硬化症间质性肺病的结局：超重悖论。
Biomedicines. 2022 Feb 13;10(2):434. doi: 10.3390/biomedicines10020434.
7
Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?从发病机制到临床表现靶向系统性硬化症：为何是白细胞介素-6？
Biomedicines. 2022 Jan 29;10(2):318. doi: 10.3390/biomedicines10020318.
8
Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.系统性硬化症的治疗选择：应对免疫介导性纤维化的现状与未来展望
Biomedicines. 2022 Jan 29;10(2):316. doi: 10.3390/biomedicines10020316.
9
Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study.双膦酸盐治疗皮肤钙质沉着症——一项回顾性单中心研究
Biomedicines. 2021 Nov 16;9(11):1698. doi: 10.3390/biomedicines9111698.
10
Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs.系统性硬化症发病机制的新观念：微小RNA的作用
Biomedicines. 2021 Oct 14;9(10):1471. doi: 10.3390/biomedicines9101471.
Zotero 插件